An observational study in Multiple Sclerosis, sponsored by Bioimmunate. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-19.
Sponsored by Bioimmunate · Observational
Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that gradually affects patient's quality of life. There are about 2.5 millions patients world wide, with an increasing cost Burdon. Up to date, it remains unclear who are the exact cells to initiate the disease. During the disease, the repertoire of cells expands and undergoes changes. The purpose of this study is to characterize those changes.
18 to 70 years old patients with MS defined according to the revised diagnostic criteria of MacDonald and are followed by the neurology or physical medicine and rehabilitation center or healthy volunteers.
Exclusion Criteria:
Patients previously diagnosed with Multiple Sclerosis
Other: Blood Sampling
Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
Other: Blood Sampling · Other: CSF Sampling
Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
Other: Blood Sampling
Blood samples will be taken from all patients and healthy volunteers.
CSF sample will be taken from hospitalized newly diagnosed patients only.
Quantification of disease related white blood cells from blood and/ or CSF
Time frame: through study completion, an average of 6 months
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.